Agoracom Blog Home

Posts Tagged ‘Nature’

Mota Ventures $MOTA.ca Closes $20,000,000 Acquisition of European Pharmaceutical Manufacturer of Natural Psilocybin Extracts $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 7:41 AM on Tuesday, June 2nd, 2020
  • The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion

VANCOUVER, BC / June 2, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) a leading ecommerce provider of CBD products to consumers in the United States and Europe, is pleased to announce the completion of its’ Cdn$20,000,000 acquisition (the “Transaction“) of all of the outstanding share capital of Verrian Ontario Ltd. (“Verrian“) effective June 1, 2020. Verrian is an established and well advanced European psychedelic medicine company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

Ryan Hoggan, CEO of the Company stated, “The massive shift towards psychedelic derived medicines is no longer in doubt and this acquisition sends a strong signal to the market that Mota Ventures intends to be a serious participant this coming decade. Unlike some companies that use psychedelics as a marketing term, this acquisition of Verrian brings Mota market ready products, world renowned addiction medicine experts, R&D facilities and a 110,000 square foot facility to make it happen. In my opinion this is the most complete psychedelic asset on the market, and therefore should immediately make Mota a market leader in the space.”

Hoggan further added, “In 2020, we have proven our e-commerce ability to acquire tens of thousands of customers and generate millions of dollars in monthly revenues from CBD sales. We intend to bring that same market expertise to bear with our psychedelics business in 2020 and far beyond.”

ACQUISTION PROVIDES MOTA WITH IMMEDIATE ENTRY INTO FAST GROWING $100 BILLION PSYCHEDELICS INDUSTRY

The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion*. Over the past decade, growing societal awareness and acceptance of mental disorders and addiction as real diseases has accelerated the push for new and innovative treatments using psychedelics, including psilocybin.

As a result, psychedelic research published back in the 50s and 60s has resurfaced and once again highlighted their curative properties. Moreover, the recent legalization of Cannabis in Canada, as well as, across 33 US states for medicinal purposes, has significantly mitigated any stigma, leading to accelerated interest and investment in the psychedelics industry.

Verrian has already developed two psilocybin products that are natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs. This is only the beginning with further products in various stages of development.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebuel, Germany. Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite.

Verrian operates three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed two psilocybin products: PSI GEN and PSI GEN+. These Psilocybin products are focused on opiate addiction reduction. As natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to the facility and equipment outlined above, Verrian has invested approximately Cdn$2,400,000 in clinical trial design and development of proprietary formulations for its psilocybin trademarked PSI-GEN products, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP and narcotics handling recertification are secured, capabilities will extend to: specialty pharmaceutical formulations; and psilocybin refinement and production for micro dosing.

In consideration for the acquisition of all of the outstanding share capital of Verrian, the Company has issued 54,347,826 common shares (the “Consideration Shares“) to the existing shareholders of Verrian at a deemed price of $0.368 per Consideration Share. 50,543,478 of the Consideration Shares are subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter. In addition to the Consideration Shares, upon closing of the Transaction, the Company has arranged for repayment of $150,000 of existing shareholder loans of Verrian, and will arrange for repayment of the balance of $950,000 within sixty days of closing.

The Company is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Company, nor has it resulted in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the Transaction, the Company has paid a finders’ fee of 5,434,783 common shares to certain arms’-length parties who have assisted in facilitating the Transaction. The Company has also paid an administrative fee of 1,086,957 common shares of the Company to a consultant who assisted with the Transaction.

We encourage shareholders and prospective investors to visit the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota Ventures is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through its powerful eCommerce business, Mota is a leading is a direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the United States through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom.

Through its German-based Verrian operation, Mota is researching and testing the efficacy and application of natural psilocybin products for the treatment of opioid and other life altering addictions. Mota is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD and other natural health products.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Ventures $MOTA.ca Signs LOI to Acquire Ecommerce Platform Leader Unified Funding, LLC, Which Generated $96.5m in Consumer Transactions in 2019 $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 1:02 PM on Saturday, May 23rd, 2020
  • Unified has a database of over one million customers and facilitated over $375,000,000(Cdn) in consumer transactions
  • Unified’s platform generates revenue from licensing, marketing and product fulfillment fees, supporting brands in skin care, essential oils, men’s health, weight management and CBD

VANCOUVER, BC / ACCESSWIRE / May 23, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company”) is excited to announce it has entered into a Letter of Intent (the “LOI”) dated May 21, 2020, to evaluate the acquisition (the “Proposed Transaction”) of Unified Funding, LLC (“Unified”). Since inception in 2015, Unified has generated a database of over one million customers and has facilitated over Cdn$375,000,000 in consumer transactions. Powered by its proprietary technology platform, Unified has created an eCommerce ecosystem to scale its brands and achieve profitability targets through data analysis, strategic customer acquisition and supply chain management. Founded by partners with more than a decade of eCommerce and technology experience, Unified has rapidly grown into a formidable business focused on aggressive expansion in the natural health products market. Unified’s diverse platform generates revenue from; licensing, marketing and product fulfillment fees supporting brands in skin care, essential oils, men’s health, weight management and CBD including MOTA’s recently audited Nature’s Exclusive brand. Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada closing exchange rate on May 22, 2020 of US$1.00:Cdn$1.3892.

“A transaction with Unified is another step forward in our expansion as a global eCommerce business. This is the platform and personnel necessary for MOTA to launch and grow brands, such as Nature’s Exclusive, which we acquired from Unified in January of 2020. Unified has developed a comprehensive eCommerce platform that is ideally suited for the natural health products sector. Integration of their platform and the personnel to run it will allow us to rapidly deploy new products and expand into new natural health product segments and markets,” stated Ryan Hoggan, CEO of the Company.

Beyond Unified’s comprehensive eCommerce technology platform, their services assist brands with launching and scaling customer acquisition strategies. Through a worldwide network of media partners, Unified is able to closely monitor market trends to guide product innovation and marketing strategies that yield profitable results.

“We have created a very comprehensive eCommerce platform with a team of data analysis, strategic customer acquisition and supply chain management experts that has been proven effective for rapid expansion of natural health brands. We are hopeful that a transaction with Mota will allow our group to use our skills to expand into additional international markets, create new natural health brands and reach more consumers. Mota’s access to capital markets to raise growth capital to invest in customer acquisition will give us a distinct advantage to quickly scale, diversify and expand into new high growth product offerings,” stated Kevin Keranen, Chairman of Unified.

Readers are cautioned that the LOI entered into with Unified does not set forth the terms of the Proposed Transaction, nor have such terms been finalized. Completion of the Proposed Transaction is subject to a number of conditions, including, not limited to, completion of due diligence, negotiation of definitive documentation, and the receipt of any required regulatory approvals. The Proposed Transaction cannot be completed until these conditions are satisfied and there can be no assurance that the Proposed Transaction will be completed at all.

The Proposed Transaction is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The Company will provide further information regarding its review of Unified, and the Proposed Transaction, as that information becomes available.

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

About Unified Funding, LLC

Founded in 2015 by partners with more than a decade of eCommerce and technology experience, Unified has rapidly grown into a formidable organization focused on aggressive expansion in the natural health products market. Powered by its proprietary technology platform, the company has created an eCommerce ecosystem to scale its brands and achieve profitability targets through data analysis, strategic customer acquisition and supply chain management. For more information about Unified, please visit https://www.unifiedbrandlab.com/.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected]or www.motaventuresco.com

Mota Ventures $MOTA.ca Talks Strategy on Mushrooms and CBD $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 9:30 AM on Thursday, May 21st, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

Results of the 2019 calendar year audit of Nature’s Exclusive:

  • Revenue of Cdn$29,034,000
  • Net income of $3,505,000
  • Achieved a margin of over 12%

VANCOUVER, BC / ACCESSWIRE / May 21, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) would like to thank all shareholders and investors for attending yesterday’s investor call. The main items addressed on the call were the completion of 2019 audit of the Nature’s Exclusive brand and the expansion of business in the natural health products sector through the proposed acquisition of Verrian.

The 2019 financial results for the Nature’s Exclusive brand is a strong indicator of the power of the Company’s eCommerce business model. This growth continued into 2020. For the months January through April 2020, the Company has generated revenue of Cdn$13,968,000 with related expenses of Cdn$13,514,000. Revenue has increased 188% for this time period over the same period during 2019. The Company’s customer acquisition and subscription retention strategies are yielding benefits through the year and into May where the Nature’s Exclusive brand has acquired over 17,613 customers from May 1st through May 18th. With over 60% of these customers electing into a subscription, the Company expects reduced costs in the following months, as customer acquisition expense is a one-time cost per customer.

As a leading business in the natural health products sector, we’ve been aggressively looking to expand our offering into growing segments of the market. Through this process, we identified psychedelic medicine as a unique opportunity, due to the overwhelming momentum of the sector and the incredible health benefits that can be obtained through derivative products.

The Company has come to terms to acquire Verrian, a leading company in the psychedelic medicine sector. Verrian owns and operates an established 110,000 square-foot pharmaceutical manufacturing facility in Germany that holds EU-GMP, ISO 14001, and narcotics manufacturing licenses. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite.

Beyond the importance of this manufacturing asset, Verrian’s product commercialization process is already underway. The business has invested over Cdn$2,000,000 in clinical trials with two studies that are ongoing. These studies combined with our manufacturing abilities will uniquely prepare us to go-to-market once approval is granted.

Verrian’s product development pipeline is incredibly strong with two products named PSI Gen and PSI Gen+, which are both natural psilocybin extracts from organic mushrooms combined with metabolism-enhancing natural herbs. While there are many benefits patients may realize from utilizing psychedelic medicine, Verrian is focusing on opioid addiction reduction. This is an important mission as a company as it is estimated that over 13 million people in the world take opioids. For those individuals who have suffered a loss due to one’s addiction to a medically prescribed pharmaceutical, this holistic approach provided by Verrian and Mota is even more meaningful. In addition to treatments for opioids, new studies have demonstrated successful psilocybin treatments for both alcoholism and depression, substantially increasing the market size of potential patients. According to Marketdata, the United States market for alcohol and drug addiction rehab will be worth $42,000,000,000 in 2020, with over 15,000 private treatment facilities and growing.

“Our acquisition of Verrian is another step forward in executing our vision to use our powerful eCommerce platform for new and innovative natural health products. While we continue to grow and expand our CBD business units, we will also be ready to fully commercialize the technology created by Verrian. I look forward to working with Verrian’s incredibly talented team of clinical researchers and addiction medicine professionals within our existing ecosystem as it will uniquely position us as a leader in psychedelic medicine,” stated Ryan Hoggan, CEO of the Company.

Completion of the acquisition of Verrian remains subject to a number of conditions, including completion of due diligence, receipt of any required regulatory approvals and the negotiation of definitive documentation. For further information regarding the proposed acquisition, readers are encouraged to review the Company’s news release of May 19, 2020.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4620

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Schedules Conference Call to Discuss Recent Announcements $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 5:20 PM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 19, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ)(OTC:PEMTF) (the “Company) a direct to consumer provider of a wide range of CBD products globally, is pleased to announce it will be hosting an investor conference call on Wednesday, May 20, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President to discuss recent announcements.

The call will be held on May 20, at 1:15 pm Pacific Time.

Conference details:

Canada/USA TF: 1-800-319-4610
International Toll: 1-604-638-5340
Germany TF: 0800-180-1954

Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4620

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com.

Mota Ventures $MOTA.ca Announces Completion Of Audit For Nature’s Exclusive Brand $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 11:31 AM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC, CANADA / ACCESSWIRE / May 19, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is pleased to announce completion of an audit of the financial results of its Nature’s Exclusive brand through the twelve-months ended December 31, 2019.

  • 2019 audited financial results:
  • Revenue of Cdn$29,034,000
  • Associated expenses of Cdn$25,530,000
  • Net income of Cdn $3,505,000

“Completion of the 2019 audit is a culmination of an extensive team effort, and represents a significant milestone in the validation of our eCommerce business. The 2019 figures, where we achieved over 12% net income, provides us with a benchmark from which to measure our success in the 2020 fiscal year as we continue to build on the strong results generated by Unified,” noted Ryan Hoggan, Chief Executive Officer of the Company.

Throughout the 2019 calendar year, the Nature’s Exclusive brand was operated as a separate business segment of Unified Funding, LLC (“Unified“). The Company completed the acquisition of the brand, and the associated business line, on January 17, 2020. The audit was completed on carve-out financial statements of Unified, which present the standalone financial results of the brand. Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada average annual exchange rate of US$1.00:Cdn$1.3269 for 2019.

The Company also announces that it has reached an agreement with Unified to amend the thresholds necessary for Unified to earn a bonus based on the financial results generated by the Nature’s Exclusive brand in the 2020 calendar year. Unified is entitled to earn a bonus payment based on the terms of the original transaction in which Mota acquired control of the brand, and the associated business line.

Under the terms of the amendment, Unified will continue to be entitled to a one-time bonus payment (the “Bonus Payment“) based on the revenue and profitability of Nature’s Exclusive in the 2020 calendar year. The Bonus Payment will be: (i) US$5,000,000, in the event gross revenue exceeds US$40,000,000 with a profit margin of at least ten percent; (ii) US$10,000,000, in the event gross revenue exceeds US$45,000,000 with a profit margin of at least ten percent; or (iii) US$15,000,000, in the event gross revenue exceeds US$50,000,000. The Bonus Payment will be payable in common shares of the Company (the “Bonus Shares“) based on an exchange rate of US$1.00 to C$1.30 and the greater of: (i) C$0.80; and (ii) the volume-weighted average closing price of the common shares of the Company on the Canadian Securities Exchange in the ten trading days prior to the last trading day of 2020. Any Bonus Shares issuable by the Company will be subject to the terms of a thirty-six month time release pooling arrangement, with applicable release dates calculated from the date of issuance of the Bonus Shares.

For further information regarding the Bonus Payment, and the acquisition of Nature’s Exclusive, readers are encouraged to review the Company’s news release of January 17, 2020.

“Revising the 2020 performance bonus will help to align our interests with Unified, and ensure they remain incentivized in the development of Nature’s Exclusive in the context of the current market. The brand has demonstrated strong financial results through 2020 to date, in spite of economic volatility and we look forward to continued success leading into the second half of 2020,” commented Ryan Hoggan, Chief Executive Officer of the Company.

About Mota Ventures Corp.

Mota is an established ecommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com